Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

288 Press Releases
DateTitleCompany
10 Dec 15 Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases Takeda ,
Published by
PharmiWeb.com
08 Dec 15 Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases Takeda Pharmaceutical Company Limited,
Published by
Business Wire
06 Dec 15 Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO® (ixazomib), First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma Takeda Pharmaceutical Company Limited,
Published by
Business Wire
02 Dec 15 Takeda Welcomes the Publication of New National Institute for Health and Care Excellence (NICE) Guidelines on the Management of Type 2 Diabetes in Adults Takeda UK Limited,
Published by
PR Newswire
30 Nov 15 "Copaxone® Subcutaneous Injection 20 mg Syringe" Now Available for the Treatment for Multiple Sclerosis in Japan Takeda Pharmaceutical ,
Published by
PharmiWeb.com
30 Nov 15 Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs of Patients and Growing Importance of Generic Medicines Use in Japan Takeda Pharmaceutical Company Limited,
Published by
Business Wire
23 Nov 15 U.S. FDA Approves Takeda’s NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma Takeda,
Published by
PharmiWeb.com
21 Nov 15 ADDING MULTIMEDIA U.S. FDA Approves Takeda’s NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma Takeda Pharmaceutical Company Limited,
Published by
Business Wire
20 Nov 15 U.S. FDA Approves Takeda’s NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma Takeda Pharmaceutical Company Limited,
Published by
Business Wire
13 Nov 15 Takeda UK strengthens its senior leadership team Takeda UK,
Published by
Liberation Unlimited
06 Nov 15 Takeda to Present Data from Ixazomib’s Phase 3 Study in Relapsed/Refractory Multiple Myeloma at Upcoming American Society of Hematology Annual Meeting Takeda ,
Published by
PharmiWeb.com
30 Oct 15 Takeda Reports Results for the First Half of FY2015 Confirms Management Guidance for the Full Year Takeda Pharmaceutical Company Limited,
Published by
Business Wire
20 Oct 15 Takeda Presents Vedolizumab Data at the 2015 American College of Gastroenterology (ACG) Annual Meeting Takeda ,
Published by
PharmiWeb.com
14 Oct 15 UCL and Takeda Announce a New Research Partnership to Identify Novel Therapeutic Targets for Neurodegenerative Diseases Takeda Pharmaceutical Company Limited,
Published by
Business Wire
02 Oct 15 Takeda Celebrates Fifth Annual Takeda Cares Day by Expanding Nationwide and Raising More Than $250,000 for Chicagoland Nonprofits Takeda Pharmaceuticals Company Limited,
Published by
PR Newswire
01 Oct 15 Takeda selected for the sixth consecutive year for Dow Jones Sustainability Asia Pacific Index Takeda ,
Published by
PharmiWeb.com
01 Oct 15 New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis Takeda ,
Published by
PharmiWeb.com
01 Oct 15 Takeda Obtained New Drug Application Approval of Leuplin® PRO for injection kit 22.5 mg in Japan for the Treatment of Prostate Cancer and Premenopausal Breast Cancer Takeda ,
Published by
PharmiWeb.com
28 Sep 15 Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis Takeda Pharmaceutical Company Limited,
Published by
Business Wire
26 Aug 15 Takeda and Nanotherapeutics Announce Agreement to Expand Takeda's Commercialization and Technology Access Rights in Support of Influenza and Other Vaccine Programs Takeda Pharmaceutical Company Limited,
Published by
Business Wire
29 Sep 15 Takeda Selected for the Sixth Consecutive Year for Dow Jones Sustainability Asia Pacific Index Takeda Pharmaceutical Company Limited,
Published by
Business Wire
29 Aug 15 Takeda and Nanotherapeutics Announce Agreement to Expand Takeda's Commercialization and Technology Access Rights in Support of Influenza and Other Vaccine Programs Takeda ,
Published by
Pharmiweb.com
29 Aug 15 Takeda Announces Appointment of New Senior Leadership Takeda ,
Published by
Pharmiweb.com
24 Sep 15 Takeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop Takeda ,
Published by
PharmiWeb.com
22 Sep 15 Takeda to Highlight Ixazomib Clinical Development Program at Upcoming International Myeloma Workshop Takeda Pharmaceutical Company Limited,
Published by
Business Wire
09 Sep 15 U.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma Takeda Pharmaceutical Company Limited,
Published by
Business Wire
01 Oct 15 Takeda Submits a New Drug Application for the Fixed-Dose Combination of Nesina® and Metformin Hydrochloride for the Treatment of Type 2 Diabetes in Japan Takeda ,
Published by
PharmiWeb.com
11 Sep 15 Gencia and Takeda Team to Discover and Develop Novel Class of Mitochondrial Therapeutics Takeda ,
Published by
PharmiWeb.com
12 Sep 15 More than 96 Percent of Claimants Opt-In to ACTOS Resolution Program; Takeda Expects Resolution to Become Effective Once Submission Review Completed; Takeda Stands Behind ACTOS Takeda Pharmaceuticals,
Published by
PR Newswire
14 Sep 15 Takeda Joins WIPO Re:Search to Accelerate R&D of New Drugs for Neglected Tropical Diseases, Malaria and TB Takeda Pharmaceutical Company Limited,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.